JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB270844

Recombinant Human coronavirus SARS spike glycoprotein (Tagged)

Be the first to review this product! Submit a review

|

(0 Publication)

Recombinant Human coronavirus SARS spike glycoprotein (Tagged) is a SARS-CoV-2 Fragment protein, expressed in Escherichia coli, with >95%, suitable for ELISA, WB, SDS-PAGE.

View Alternative Names

2, S, Spike glycoprotein, S glycoprotein, E2, Peplomer protein

3 Images
Indirect ELISA - Recombinant Human coronavirus SARS spike glycoprotein (Tagged) (AB270844)
  • I-ELISA

Lab

Indirect ELISA - Recombinant Human coronavirus SARS spike glycoprotein (Tagged) (AB270844)

Indirect ELISA showing primary antibody ab323001 binding to Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera, ab272105). Plates were coated with Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera, ab272105), Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S2 (Fc Chimera, ab272106) and Recombinant Human coronavirus SARS spike glycoprotein (Tagged, ab270844) at 1000 ng/ml. Binding of ab323001 was assessed in a serial dilution range 0.016- 1000 ng/mL (a 3-fold serial dilution). Secondary antibody, Goat Anti-Chicken IgY H&L (HRP, ab6877) was used at 1 : 5000.

Indirect ELISA - Recombinant Human coronavirus SARS spike glycoprotein (Tagged) (AB270844)
  • I-ELISA

Lab

Indirect ELISA - Recombinant Human coronavirus SARS spike glycoprotein (Tagged) (AB270844)

Indirect ELISA showing primary antibody ab323000 binding to Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera, ab272105). Plates were coated with Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera, ab272105), Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S2 (Fc Chimera, ab272106) and Recombinant human coronavirus SARS spike glycoprotein (Tagged, ab270844) at 1000 ng/ml. Binding of ab323000 was assessed in a serial dilution range 0.016- 1000 ng/mL (a 3-fold serial dilution). Secondary antibody, Goat Anti-Human IgG Fc (HRP) preadsorbed (ab98624) was used at 1 : 5000.

Indirect ELISA - Recombinant Human coronavirus SARS spike glycoprotein (Tagged) (AB270844)
  • I-ELISA

Lab

Indirect ELISA - Recombinant Human coronavirus SARS spike glycoprotein (Tagged) (AB270844)

Indirect ELISA showing primary antibody ab322999 binding to Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera, ab272105). Plates were coated with Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera, ab272105), Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S2 (Fc Chimera, ab272106) and Recombinant Human coronavirus SARS spike glycoprotein (Tagged, ab270844) at 1000 ng/ml. Binding of ab322999 was assessed in a serial dilution range 0.016- 1000 ng/mL (a 3-fold serial dilution). Secondary antibody, Goat Anti-Chicken IgY H&L (HRP, ab6877) was used at 1 : 5000.

Key facts

Purity

>95% SDS-PAGE

Expression system

Escherichia coli

Tags

GST tag C-Terminus

Applications

WB, ELISA, SDS-PAGE

applications

Biologically active

No

Accession

P0DTC2

Animal free

No

Carrier free

No

Species

SARS-CoV-2

Storage buffer

Constituents: 50% Glycerol (glycerin, glycerine), 0.4% Tris HCl, 0.4% Sodium-N-Lauroylsarcosinate, 0.25% Triton X-100

storage-buffer

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "ELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p>May appear as multiple bands on SDS-PAGE (intact protein at 38 kDa, GST fusion protein at 26 kDa and the Nucleocapsid fragment at 12 kDa).</p>" } } }

Product details

Contains GST fusion partner. Immunoreactive with SARS positive sera.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Sequence info

[{"sequence":"","proteinLength":"Fragment","predictedMolecularWeight":"38 kDa","actualMolecularWeight":null,"aminoAcidEnd":0,"aminoAcidStart":0,"nature":"Recombinant","expressionSystem":null,"accessionNumber":null,"tags":[{"tag":"GST","terminus":"C-Terminus"}]}]

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
False

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The SARS spike glycoprotein also known as the S glycoprotein is a critical component of the SARS-CoV-2 virus. It weighs approximately 180 kDa and can be found on the surface of the viral envelope. The spike glycoprotein facilitates the entry of the virus into host cells by binding to the angiotensin-converting enzyme 2 (ACE2) receptor. This protein is often targeted by monoclonal antibodies and vaccine strategies aimed at preventing infection. Researchers isolate antibodies that bind specifically to the spike contributing to the development of therapeutic agents like anti-spike monoclonal antibodies.
Biological function summary

The spike glycoprotein serves a fundamental role in the viral life cycle by mediating fusion between the viral membrane and host cell membranes. Its function is divided into two subunits: S1 which is responsible for receptor binding and S2 which is important for membrane fusion. Upon receptor binding a conformational change in the glycoprotein occurs triggering fusion events critical for viral entry. This protein is not typically part of a larger complex but operates in tandem with viral envelope proteins to facilitate replication.

Pathways

The spike glycoprotein's interaction with the host cell's ACE2 receptor places it within the renin-angiotensin-aldosterone system (RAAS) affecting several downstream signaling pathways. The binding initiates endocytosis of the virus into the host cell and impacts inflammation pathways and immune response mechanisms involving interleukin proteins. The spike protein shares functional relationships with other viral proteins such as nucleocapsid and membrane proteins contributing to the virion's structure and infection process.

The spike glycoprotein is closely associated with COVID-19 and the disease's ability to spread and mutate. It's a central focus in the development of potential treatments and vaccines given its role in viral entry. Some mutations in the spike protein can enhance transmissibility or resistance to neutralization influencing the course of infection. In seeking therapeutic interventions researchers focus on spike-related interactions with host proteins like ACE2 which are important in managing COVID-19 symptoms and complications.

Specifications

Form

Liquid

Additional notes

GS-4B Sepharose-Affinity Purification.

General info

Function

Spike protein S1. Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. The major receptor is host ACE2 (PubMed : 32142651, PubMed : 32155444, PubMed : 33607086). When S2/S2' has been cleaved, binding to the receptor triggers direct fusion at the cell membrane (PubMed : 34561887). When S2/S2' has not been cleaved, binding to the receptor results in internalization of the virus by endocytosis leading to fusion of the virion membrane with the host endosomal membrane (PubMed : 32075877, PubMed : 32221306). Alternatively, may use NRP1/NRP2 (PubMed : 33082294, PubMed : 33082293) and integrin as entry receptors (PubMed : 35150743). The use of NRP1/NRP2 receptors may explain the tropism of the virus in human olfactory epithelial cells, which express these molecules at high levels but ACE2 at low levels (PubMed : 33082293). The stalk domain of S contains three hinges, giving the head unexpected orientational freedom (PubMed : 32817270).. Spike protein S2. Precursor of the fusion protein processed in the biosynthesis of the S protein and the formation of virus particle. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains two viral fusion peptides that are unmasked after cleavage. The S2/S2' cleavage occurs during virus entry at the cell membrane by host TMPRSS2 (PubMed : 32142651) or during endocytosis by host CSTL (PubMed : 32703818, PubMed : 34159616). In either case, this triggers an extensive and irreversible conformational change leading to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed : 34561887). Under the current model, the protein has at least three conformational states : pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes.. Spike protein S2'. Subunit of the fusion protein that is processed upon entry into the host cell. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains a viral fusion peptide that is unmasked after S2 cleavage. This cleavage can occur at the cell membrane by host TMPRSS2 or during endocytosis by host CSTL (PubMed : 32703818, PubMed : 34159616). In either case, this triggers an extensive and irreversible conformational change that leads to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed : 34561887). Under the current model, the protein has at least three conformational states : pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes.

Sequence similarities

Belongs to the betacoronaviruses spike protein family.

Post-translational modifications

The cytoplasmic Cys-rich domain is palmitoylated. Palmitoylated spike proteins drive the formation of localized ordered cholesterol and sphingo-lipid-rich lipid nanodomains in the early Golgi, where viral budding occurs.. Specific enzymatic cleavages in vivo yield mature proteins. The precursor is processed into S1 and S2 by host furin or unknown proteases to yield the mature S1 and S2 proteins (PubMed:32155444, PubMed:32362314, PubMed:32703818, PubMed:34159616, PubMed:34561887). Processing between S2 and S2' occurs either by host CTSL in endosomes (PubMed:32221306, PubMed:33465165, PubMed:34159616), or by host TMPRSS2 at the cell surface (PubMed:32142651). Both cleavages are necessary for the protein to be fusion competent (PubMed:32703818, PubMed:34159616, PubMed:34561887). Cell surface activation allows the virus to enter the cell despite inhibition of the endosomal pathway by hydroxychloroquine (PubMed:33465165). The polybasic furin cleavage site is absent in SARS-CoV S (PubMed:32155444, PubMed:32362314, PubMed:33465165). It increases the dependence on TMPRSS2 expression by SARS-CoV-2 (PubMed:33465165). D614G substitution would enhance furin cleavage at the S1/S2 junction (PubMed:33417835).. Highly decorated by heterogeneous N-linked glycans protruding from the trimer surface (PubMed:32075877, PubMed:32155444, PubMed:32929138). Highly glycosylated by host both on S1 and S2 subunits, occluding many regions across the surface of the protein (PubMed:32363391, PubMed:32366695, PubMed:32929138). Approximately 40% of the protein surface is shielded from antibody recognition by glycans, with the notable exception of the ACE2 receptor binding domain (PubMed:32929138).. O-glycosylated by host GALNT1 at the end of S1. This could reduce the efficiency of S1/S2 cleavage.

Product protocols

Target data

Spike protein S1. Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. The major receptor is host ACE2 (PubMed : 32142651, PubMed : 32155444, PubMed : 33607086). When S2/S2' has been cleaved, binding to the receptor triggers direct fusion at the cell membrane (PubMed : 34561887). When S2/S2' has not been cleaved, binding to the receptor results in internalization of the virus by endocytosis leading to fusion of the virion membrane with the host endosomal membrane (PubMed : 32075877, PubMed : 32221306). Alternatively, may use NRP1/NRP2 (PubMed : 33082294, PubMed : 33082293) and integrin as entry receptors (PubMed : 35150743). The use of NRP1/NRP2 receptors may explain the tropism of the virus in human olfactory epithelial cells, which express these molecules at high levels but ACE2 at low levels (PubMed : 33082293). The stalk domain of S contains three hinges, giving the head unexpected orientational freedom (PubMed : 32817270).. Spike protein S2. Precursor of the fusion protein processed in the biosynthesis of the S protein and the formation of virus particle. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains two viral fusion peptides that are unmasked after cleavage. The S2/S2' cleavage occurs during virus entry at the cell membrane by host TMPRSS2 (PubMed : 32142651) or during endocytosis by host CSTL (PubMed : 32703818, PubMed : 34159616). In either case, this triggers an extensive and irreversible conformational change leading to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed : 34561887). Under the current model, the protein has at least three conformational states : pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes.. Spike protein S2'. Subunit of the fusion protein that is processed upon entry into the host cell. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains a viral fusion peptide that is unmasked after S2 cleavage. This cleavage can occur at the cell membrane by host TMPRSS2 or during endocytosis by host CSTL (PubMed : 32703818, PubMed : 34159616). In either case, this triggers an extensive and irreversible conformational change that leads to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed : 34561887). Under the current model, the protein has at least three conformational states : pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes.
See full target information S

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com